VERTEX PHARMACEUTICAL COM STK USD0.01VERTEX PHARMACEUTICAL COM STK USD0.01VERTEX PHARMACEUTICAL COM STK USD0.01

VERTEX PHARMACEUTICAL COM STK USD0.01

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪126.19 B‬USD
−1.85USD
‪3.62 B‬USD
‪9.84 B‬USD
‪256.86 M‬
Beta (1Y)
1.09
Employees (FY)
‪5.4 K‬
Change (1Y)
+600 +12.50%
Revenue / Employee (1Y)
‪1.82 M‬USD
Net income / Employee (1Y)
‪670.30 K‬USD

About Vertex Pharmaceuticals Incorporated


CEO
Reshma Kewalramani
Headquarters
Boston
Website
Founded
1989
FIGI
BBG00JRYC2N1
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0QZU is 494.20 USD — it has decreased by −0.71% in the past 24 hours. Watch VERTEX PHARMACEUTICAL COM STK USD0.01 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange VERTEX PHARMACEUTICAL COM STK USD0.01 stocks are traded under the ticker 0QZU.
0QZU stock has fallen by −1.94% compared to the previous week, the month change is a 2.71% rise, over the last year VERTEX PHARMACEUTICAL COM STK USD0.01 has showed a 29.89% increase.
We've gathered analysts' opinions on VERTEX PHARMACEUTICAL COM STK USD0.01 future price: according to them, 0QZU price has a max estimate of 602.00 USD and a min estimate of 325.00 USD. Watch 0QZU chart and read a more detailed VERTEX PHARMACEUTICAL COM STK USD0.01 stock forecast: see what analysts think of VERTEX PHARMACEUTICAL COM STK USD0.01 and suggest that you do with its stocks.
0QZU reached its all-time high on Nov 8, 2024 with the price of 516.50 USD, and its all-time low was 145.95 USD and was reached on Jun 7, 2018. View more price dynamics on 0QZU chart.
See other stocks reaching their highest and lowest prices.
0QZU stock is 1.67% volatile and has beta coefficient of 1.09. Track VERTEX PHARMACEUTICAL COM STK USD0.01 stock price on the chart and check out the list of the most volatile stocks — is VERTEX PHARMACEUTICAL COM STK USD0.01 there?
Today VERTEX PHARMACEUTICAL COM STK USD0.01 has the market capitalization of ‪126.19 B‬, it has increased by 9.29% over the last week.
Yes, you can track VERTEX PHARMACEUTICAL COM STK USD0.01 financials in yearly and quarterly reports right on TradingView.
VERTEX PHARMACEUTICAL COM STK USD0.01 is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
0QZU earnings for the last quarter are 4.38 USD per share, whereas the estimation was 4.08 USD resulting in a 7.41% surprise. The estimated earnings for the next quarter are 4.07 USD per share. See more details about VERTEX PHARMACEUTICAL COM STK USD0.01 earnings.
VERTEX PHARMACEUTICAL COM STK USD0.01 revenue for the last quarter amounts to ‪2.77 B‬ USD, despite the estimated figure of ‪2.69 B‬ USD. In the next quarter, revenue is expected to reach ‪2.78 B‬ USD.
0QZU net income for the last quarter is ‪1.05 B‬ USD, while the quarter before that showed ‪−3.59 B‬ USD of net income which accounts for 129.09% change. Track more VERTEX PHARMACEUTICAL COM STK USD0.01 financial stats to get the full picture.
No, 0QZU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 14, 2024, the company has ‪5.40 K‬ employees. See our rating of the largest employees — is VERTEX PHARMACEUTICAL COM STK USD0.01 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VERTEX PHARMACEUTICAL COM STK USD0.01 EBITDA is ‪−88.10 M‬ USD, and current EBITDA margin is 45.32%. See more stats in VERTEX PHARMACEUTICAL COM STK USD0.01 financial statements.
Like other stocks, 0QZU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMACEUTICAL COM STK USD0.01 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VERTEX PHARMACEUTICAL COM STK USD0.01 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VERTEX PHARMACEUTICAL COM STK USD0.01 stock shows the buy signal. See more of VERTEX PHARMACEUTICAL COM STK USD0.01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.